Emblem Corp. and Dosecann Inc. Sign Licensing Deal to Develop Dosage-Controlled Formulations

Agreement Paves Way for More Accessible Dosing and More Consistent Delivery Systems

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TORONTO, Dec. 21, 2017 -- **Emblem Corp.** (TSX-V:EMC) (EMC.WT) **("Emblem"** or the **"Company")**, has entered into a licensing agreement with **Dosecann Inc.** ("**Dosecann"**) pursuant to which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way.

The two companies will begin work immediately on the development of a cannabis-oil oral spray dosage form, followed by the development of two separate dose-controlled vaporizers.

"We are very excited about our relationship with Dosecann," says Nick Dean, President and CEO of Emblem Corp. "We are focused on and committed to investing in pharmaceutical research and development and bringing more medically-focused products to market. We expect that these dosage-controlled products will have a major impact on the Canadian medical cannabis market and we're looking forward to further collaborations with Dosecann to bring other value-added cannabis based metered-dosage forms to the market."

The licensing agreement involves a number of research related aspects including research into pre-clinical formulations, clinical development, as well as regulatory approval, manufacturing and the commercialization and distribution of a range of cannabinoid dosage forms.

The agreement provides for both Emblem and Dosecann to commercialize branded versions of the products, targeting specific markets and with different cannabinoid profiles.

Dosecann will receive royalty payments from Emblem on sales of Emblem-branded products and Emblem with receive royalties from Dosecann on sales of Dosecann-branded products.

"There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including chronic pain, nausea, and spasticity in patients with Multiple Sclerosis," says John Stewart, President of Emblem's Pharmaceutical Division. "These advanced dosage forms and the whole strain extracts they contain are designed and formulated to enhance the therapeutic benefits available from medical cannabis."

About Emblem
Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on Toronto Venture Exchange (TSXV).

About Dosecann
Dosecann Inc. is a PEI-based Licensed Dealer applicant currently completing the buildout of a 45,000 square foot GMP compliant facility. Within the purpose-built facility, Dosecann intends to accommodate product development, extraction, formulation, filling and packaging. Dosecann is developing a suite of cannabis products across a variety of delivery methods for both the medical and adult use markets.

Forward-looking statements

*This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation (together, "**forward-looking statement**s"). All statements and information contained herein that is not clearly historical in nature may constitute forward-looking statement. Forward-looking statements are necessarily* *based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.*

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com

Michael Curtis
Vice President, Corporate Development
Dosecann Inc.
(416) 315-1895
Michael.curtis@dosecann.com